MedTrace Logo

Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response

NCT00518154 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2019-11-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether the addition of Pyridostigmine to Highly Active Antiretroviral Therapy (HAART) increases the number of CD4+ T-cells in discordant patients in which viral load diminishes, but T-cell levels remain low after the initiation of treatment.

Conditions

  • HIV Infections

Interventions

DRUG

Pyridostigmine tablets

Patients will take 30mg tid PO for 12 weeks

Sponsors & Collaborators

  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

    lead OTHER

Principal Investigators

  • Juan Sierra-Madero, MD · Dept. of Infectious Diseases, INNSZ

  • Jorge Alcocer-Varela, MD · Dept. of Immunology, INNSZ

  • Sergio I Valdés-Ferrer, MD, PhD · Dept. of Neurology, INNSZ

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-11-30
Completion
2009-01-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00518154 on ClinicalTrials.gov